| |
 Recent Articles
Drlica K, Schmitz FJ.
Therapeutic options in an era of decreasing antimicrobial
susceptibility. Therapeutic options in an era of decreasing antimicrobial
susceptibility.
J Chemother 2002 Feb;14 Suppl 2:5-12
PMID: 12003139
Antimicrobial resistance among human pathogens has evolved to the
multidrug-resistant phase. Consequently, preserving antimicrobial
efficacy is
now an important clinical consideration when selecting an agent
for therapy. A
new, in vitro measure of potency called the mutant prevention concentration
(MPC) allows clinicians to select antibacterials on the basis of
an agent's
ability to restrict the selection of resistant mutants. With some
pathogens,
C-8-methoxy fluoroquinolones are expected to be quite effective
at restricting
the selection of resistance because the value of MPC is below the
human serum
drug concentration achieved with standard doses. Clinical trials
are now needed
to determine how well preclinical profiles of these drugs correlate
with the
prevention of resistance.
|
